The group's principal activity is to engage in research and development of novel therapeutic and diagnostic products. These products help to treat chronic debilitating diseases such as alzheimer's, cancer, central nervous system disorders, cardiovascular disease, HIV and Parkinson's disease. The group is in its development stage and none of its proprietary products has reached a commercial stage. It operates solely in the domestic market.
